US20010049396A1 - Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma - Google Patents

Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma Download PDF

Info

Publication number
US20010049396A1
US20010049396A1 US09/367,950 US36795099A US2001049396A1 US 20010049396 A1 US20010049396 A1 US 20010049396A1 US 36795099 A US36795099 A US 36795099A US 2001049396 A1 US2001049396 A1 US 2001049396A1
Authority
US
United States
Prior art keywords
formoterol
asthma
budesonide
active ingredient
previous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/367,950
Other languages
English (en)
Inventor
Tommy Ekstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20411658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20010049396(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra AB filed Critical Astra AB
Assigned to ASTRA AKTIEBOLAG reassignment ASTRA AKTIEBOLAG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EKSTROM, TOMMY
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB CERTIFICATE OF REGISTRATION Assignors: ASTRA AKTIEBOLAG
Publication of US20010049396A1 publication Critical patent/US20010049396A1/en
Priority to US10/665,240 priority Critical patent/US9295644B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Definitions

  • the present invention relates to use of a composition for symptomatic relief, when needed, comprising, in admixture
  • the invention further relates to a method for prevention or treatment of an acute condition of asthma and/or intermittent asthma and/or episodes in chronic asthma by administering, by inhalation, a composition comprising the first and second active ingredients as defined previously.
  • asthma Despite recent advances in the awareness of asthma and the introduction of powerful and effective anti-asthma drugs, asthma remains a poorly understood and frequently poorly treated disease. There have been recent advances in the treatment of the disease which result from the recognition that asthma is a chronic inflammatory disease. Therapy is now aimed at both controlling the symptoms and reducing the inflammation. The symptoms may be controlled by ⁇ 2 -adrenoceptor agonists such as terbutaline, salbutamol, formoterol and salmeterol. Prophylactic therapy is typically provided by steroids such asbeclomethasone dipropionate, fluticasone propionate, mometasone furoate and budesonide.
  • steroids such asbeclomethasone dipropionate, fluticasone propionate, mometasone furoate and budesonide.
  • composition for symptomatic relief when needed comprising, in admixture
  • a second active ingredient which is budesonide for the manufacture of a medicament for use in the prevention or treatment of an acute condition of asthma and/or intermittent asthma and/or episodes in chronic asthma.
  • composition when needed, relates to use of said composition during one or more of the following conditions:
  • Acute asthma attacks may occur on an irregular basis when exposed to an agent e.g. during the pollen season, a virus infection, cold air, perfumes or any other agent(s) triggering an asthma attack in the patient.
  • compositions comprising active compounds (a) and (b) for treating acute conditions of asthma, intermittent asthma and episodes in chronic asthma, in addition to treating chronic asthma on a regular basis, with the same active compounds (a) and (b) or one or more different active compounds, preferably selected from short-acting ⁇ -agonists, long-acting ⁇ -agonists and glucocorticosteroids.
  • a method of prevention or treatment of an acute condition of asthma and/or intermittent asthma and/or episodes in chronic asthma, when needed which comprises administering, by inhalation, to a patient an effective amount of a composition comprising, in admixture:
  • the medicament can be administered when needed to a patient with an acute attack of asthma.
  • the combination of formoterol and budesonide can be used as a rescue medication. Worsening of symptoms can be counteracted by incremental use of the combination for symptom relief, e.g. during exacerbations with the additional steroid component coming in as early as possible to suppress the enhanced airway inflammation.
  • the long duration of formoterol will reduce the risk of too frequent dosing.
  • When taking the combination budesonide/formoterol when needed the severity of exacerbations can be reduced.
  • the as needed use (Pro Re Nata, PRN) will also minimize the difficulty of predicting which patients will be controlled on a low dose of inhaled steroid rather than increasing the steroid dose before adding a long-acting ⁇ 2 -agonist.
  • Under-treatment with inhaled glucocorticosteroids following a too low maintenance dose will be more or less “selfcorrected” by the rescue usage according to the present invention.
  • the PRN use of the combination will always give some beneficial anti-inflammatory effects even if it is used by the patient only for rescue purposes.
  • a treatment for patients suffering from respiratory disease, particularly asthma will therefore be to use the combination formoterol/budesonide for maintenance therapy as well as on an as needed basis (for rescue purposes). e.g. for prevention of exercise and/or allergen induced asthma.
  • Formoterol is a compound which can exist in several stereochemical forms.
  • the present invention includes the individual stereoisomers as well as mixtures thereof. It is intended that the present invention includes geometrical isomers, rotational isomers. racemates, diastereomers and enantiomers. in particular the R,R enantiomer of formoterol.
  • Suitable physiologically salts of formoterol include acid addition salts derived from inorganic and organic acids such as the hydrochloride. hydrobronide, sulfate, phosphate. maleate, fumarate, tartrate, citrate. benzoate, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, p-toluenesulphonate, methanesulphonate, ascorbate, salicylate, acetate. succinate, lactate, glutarate, gluconate, tricarballylate, hydroxy-naphthalene-carboxylate or oleate.
  • Formoterol is preferably used in the form of its fumarate salt and as a dihydrate of this salt.
  • compositions comprising the 22 R epimer of budesonide as the second active ingredient.
  • a suitable unit dose of formoterol (as fumarate dihydrate) is in the range of from 1 ⁇ g to 48 ⁇ g, preferably from 2 ⁇ g to 24 ⁇ g, and more preferably between 3 ⁇ g and 12 ⁇ g.
  • the daily dose of formoterol (as fumarate dihydrate), including maintenance therapy, should be in the range of from 1 ⁇ g to 100 ⁇ g, preferably from 2 ⁇ g to 60 ⁇ g, and more preferably from 3 ⁇ g to of 48 ⁇ g.
  • a suitable unit dose of budesonide is in the range of from 20 ⁇ g to 1600 ⁇ g, suitably from 30 ⁇ g to 800 ⁇ g, preferably from 50 ⁇ g to 400 ⁇ g, and more preferably between 100 ⁇ g and 200 ⁇ g.
  • the daily dose of budesonide, including maintenance therapy, should be in the range of 20 ⁇ g to 4800 ⁇ g, preferably from 30 ⁇ g to 3200 ⁇ g, and more preferably from 40 ⁇ g to 1600 ⁇ g.
  • the particular dose regimen will depend on the patient (age, sex, weight etc.) and the severity of the disease (mild, moderate, severe asthma etc.).
  • the molar ratio of the first active ingredient (as formoterol) to the second active ingredient of the invention suitably lies in the range of from 1:1 to 1:100, preferably from 1:1 to 1:70, and more preferably from 1:1 to 1:50.
  • the mixture comprises one or more pharmaceutically acceptable additives, diluents or carriers, more preferably in an amount of from 50 ⁇ g to 4000 ⁇ g in each dose, most preferably in an amount of from 100 ⁇ g to 2000 ⁇ g and most preferably from 100 ⁇ g to 1000 ⁇ g.
  • suitable additives, diluents or carriers include lactose, dextran, mannitol or glucose.
  • lactose is used, and more preferably as the monohydrate.
  • One or more of the ingredients of the mixture may be in the form of dry powder, more preferably a small particle dry powder, most preferably an agglomerated small particle dry powder.
  • one or more of the active ingredients (a) or (b) are in the form of an ordered mixture with diluent, additive or carrier.
  • the ingredients used in the invention can be obtained in these preferred forms using methods known to those skilled in the art.
  • the particle size of the active ingredients is preferably less than 10 ⁇ m.
  • Administration may be by inhalation orally or intranasally.
  • the ingredients of the system are preferably adapted to be administered from a dry powder inhaler, a pressurized metered dose inhaler, or a nebulizer.
  • the ingredients of the system are preferably in a small particle form. They are dissolved, or, preferably, suspended in a liquid propellant mixture.
  • the propellants which can be used include chlorofluorocarbons, hydrocarbons or hydrofluorocarbons.
  • Especially preferred propellants are P134a (tetrafluoroethane), P152a (difluoroethane) and P227 (heptafluropropane) each of which may be used alone or in combination. They are optionally used in combination with one or more other propellants and/or one or more surfactants and/or one or more other excipients, for example ethanol, a lubricant, an antioxidant and/or a stabilizing agent.
  • ingredients of the system of the invention are adapted to be administered via a nebulizer they may be in the form of a nebulized aqueous suspension or solution, with or without suitable pH or tonicity adjustment, either as a unit dose or multidose formulation.
  • micronization is carried out in a conventional manner such that the particle size range for each component is suitable for administration by inhalation.
  • Turbuhaler is a trademark of Astra AB.
  • a patient on maintenance treatment with the fixed combination formoterol fumarate dihydrate/budesonide in a dose of 4.5/80 ⁇ g or 4.5/160 ⁇ g bid additionally uses the same combination either for rescue purposes once or twice daily to treat sporadic breakthrough symptoms, or as needed to treat exacerbations during one or two weeks, with a maximum daily dose of 36/640 ⁇ g (8 puffs of 4.5/80 ⁇ g) and 36/1280 ⁇ g (8 puffs of 4.5/160 ⁇ g), respectively.
  • a patient with intermittent asthma uses the fixed combination formoterol fumarate dihydrate/budesonide as sole medication to be taken as needed until the asthma resolves.
  • the highest recommended daily dose will be either 36/640 ⁇ g (8 puffs of 4.5/80 ⁇ g) or 36/1280 ⁇ g (8 puffs of 4.5/160 ⁇ g) for a period not exceeding 8-120 weeks. If symptoms still persist after that period of time—regular maintenance therapy should be considered.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
US09/367,950 1998-06-11 1999-06-10 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma Abandoned US20010049396A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/665,240 US9295644B2 (en) 1998-06-11 2003-09-19 Methods and compositions for treating asthma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802073A SE9802073D0 (sv) 1998-06-11 1998-06-11 New use
SE9802073-8 1998-06-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1999/001031 A-371-Of-International WO1999064014A1 (en) 1998-06-11 1999-06-10 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/665,240 Continuation US9295644B2 (en) 1998-06-11 2003-09-19 Methods and compositions for treating asthma

Publications (1)

Publication Number Publication Date
US20010049396A1 true US20010049396A1 (en) 2001-12-06

Family

ID=20411658

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/367,950 Abandoned US20010049396A1 (en) 1998-06-11 1999-06-10 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
US10/665,240 Expired - Lifetime US9295644B2 (en) 1998-06-11 2003-09-19 Methods and compositions for treating asthma

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/665,240 Expired - Lifetime US9295644B2 (en) 1998-06-11 2003-09-19 Methods and compositions for treating asthma

Country Status (34)

Country Link
US (2) US20010049396A1 (cs)
EP (3) EP1085877B1 (cs)
JP (1) JP2002517450A (cs)
KR (1) KR20010052721A (cs)
CN (1) CN100389771C (cs)
AR (1) AR018410A1 (cs)
AT (1) ATE389409T1 (cs)
AU (1) AU771715B2 (cs)
BR (1) BR9911073A (cs)
CA (1) CA2334411C (cs)
CY (1) CY1110376T1 (cs)
CZ (1) CZ300874B6 (cs)
DE (1) DE69938390T2 (cs)
DK (1) DK1085877T3 (cs)
EE (1) EE05661B1 (cs)
ES (1) ES2302384T3 (cs)
HU (1) HUP0103108A3 (cs)
ID (1) ID27937A (cs)
IL (2) IL139921A0 (cs)
IS (1) IS5752A (cs)
MY (1) MY129281A (cs)
NO (3) NO20006253L (cs)
NZ (1) NZ536279A (cs)
PL (1) PL344665A1 (cs)
PT (1) PT1085877E (cs)
RU (1) RU2222332C2 (cs)
SA (1) SA99200234B1 (cs)
SE (1) SE9802073D0 (cs)
SK (1) SK286252B6 (cs)
TR (1) TR200003666T2 (cs)
TW (1) TWI252756B (cs)
UA (1) UA87956C2 (cs)
WO (1) WO1999064014A1 (cs)
ZA (1) ZA200006943B (cs)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129245A1 (en) * 2000-05-19 2003-07-10 Eva Trofast Novel process
US20070098644A1 (en) * 2005-10-31 2007-05-03 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
US20070207091A1 (en) * 2006-03-01 2007-09-06 Mcaffer Ian G C Nebulizer Formulation
US10226421B2 (en) 2013-04-10 2019-03-12 Zambon S.P.A. Pharmaceutical composition containing budesonide and formoterol
US10716753B2 (en) 2009-05-29 2020-07-21 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
US20210308150A1 (en) * 2010-07-16 2021-10-07 Cipla Limited Pharmaceutical Compositions

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
DZ3358A1 (fr) 2000-05-22 2001-11-29 Chiesi Farma Spa Formulations en solution pharmaceutiques pour inhalateurs-doseurs sous pression
ES2222294T3 (es) 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
JP4837892B2 (ja) * 2001-11-01 2011-12-14 ネクター セラピューティクス 粉末バッチを製造する方法
FI20020126A0 (fi) * 2002-01-23 2002-01-23 Orion Corp Koostumuksia pulmonaaliseen antoon
SE0200312D0 (sv) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
JP4744876B2 (ja) * 2002-08-21 2011-08-10 ノートン・ヘルスケアー リミテッド 乾燥粉末吸入組成物の製造方法
GB0219512D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
CN101677954A (zh) 2007-02-11 2010-03-24 Map药物公司 治疗性施用dhe用于快速减轻偏头痛而使副作用分布最小化的方法
JP2010519195A (ja) 2007-02-19 2010-06-03 シプラ・リミテッド 薬学的組成物
EP1982709A1 (en) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
EP2538922B1 (en) * 2010-02-25 2016-04-06 Andi-Ventis Limited Formulation of compositions for the treatment of inflammatory conditions
CA2809666C (en) 2010-08-30 2020-09-22 Michael M. Lipp Dry powder formulations and methods for treating pulmonary diseases
WO2012030645A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
DK3470057T3 (da) 2010-09-29 2021-11-22 Pulmatrix Operating Co Inc Kationiske tørpulvere omfattende magnesiumsalt
CA3086367A1 (en) 2010-09-29 2012-04-05 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
JP2015509788A (ja) 2012-02-29 2015-04-02 パルマトリックス，インコーポレイテッド 吸入に適した乾燥粉末
RU2504382C1 (ru) * 2012-06-13 2014-01-20 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
CA2907566C (en) 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
TW201735914A (zh) * 2015-12-22 2017-10-16 阿斯特捷利康公司 用於治療慢性阻塞性肺疾病之醫藥組成物
IT202000006442A1 (it) * 2020-03-27 2021-09-27 Genetic S P A Budesonide 21-phosphate salts and pharmaceutical compositions containing the same

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250286A (en) * 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
US5674860A (en) * 1991-12-18 1997-10-07 Astra Aktiebolag Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders
US5684199A (en) * 1993-12-28 1997-11-04 Novartis Corporation Process for the preparation of an optically pure enantiomer of formoterol
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5996576A (en) * 1995-09-27 1999-12-07 Glaxo Group Limited Atomising nozzle
US6030604A (en) * 1997-01-20 2000-02-29 Astra Aktiebolag Formulation for inhalation
US6227862B1 (en) * 1999-02-12 2001-05-08 Advanced Drivers Education Products And Training, Inc. Driver training system
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203401A (en) 1979-01-29 1980-05-20 General Motors Corporation Evaporative emissions canister
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
JP3042866B2 (ja) 1989-09-08 2000-05-22 グラクソ・グループ・リミテッド 呼吸疾患治療薬
PL164294B1 (pl) 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5119791A (en) 1991-06-07 1992-06-09 General Motors Corporation Vapor storage canister with liquid trap
US5444521A (en) 1991-07-15 1995-08-22 Canon Kabushiki Kaisha Image fixing device capable of controlling heating overshoot
EP1101493A3 (en) 1991-12-18 2004-01-14 AstraZeneca AB New combination of formoterol and budesonide
US5408977A (en) 1993-08-23 1995-04-25 Walbro Corporation Fuel tank with carbon canister and shut-off valve
EG20677A (en) 1993-10-01 1999-11-30 Astra Ag Method and an apparatus for micronizing the particle size
US5511957A (en) 1994-09-27 1996-04-30 Walbro Corporation High capacity fuel pump and filter combination
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
WO1997021680A1 (en) 1995-11-24 1997-06-19 Smithkline Beecham S.P.A. Quinoline derivatives
US5651349A (en) 1995-12-11 1997-07-29 Chrysler Corporation Purge system flow monitor and method
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
BR9810452A (pt) 1997-06-27 2000-09-05 Astra Ab Nova combinação de medicamentos contra asma
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US5957114A (en) 1998-07-17 1999-09-28 Ford Motor Company Evaporative emission canister for an automotive vehicle
US5924410A (en) 1998-07-20 1999-07-20 Ford Motor Company Evaporative emission canister for an automotive vehicle
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
EP1031725B1 (en) 1999-02-26 2004-12-29 Walbro Corporation Vehicle fuel system
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
US6237574B1 (en) 1999-04-20 2001-05-29 Ford Motor Company Evaporative emission canister for an automotive vehicle
US6136075A (en) 1999-05-03 2000-10-24 Westvaco Corporation Automotive evaporative emissions canister adsorptive restraint system
JP3646217B2 (ja) 1999-07-08 2005-05-11 愛三工業株式会社 キャニスタモジュール
US6374811B1 (en) 2000-10-04 2002-04-23 Ford Global Technologies, Inc. System and method for minimizing fuel evaporative emissions from an internal combustion engine

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250286A (en) * 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5674860A (en) * 1991-12-18 1997-10-07 Astra Aktiebolag Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders
US5972919A (en) * 1991-12-18 1999-10-26 Astra Aktiebolag Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders, as well as its use and the preparation thereof
US5684199A (en) * 1993-12-28 1997-11-04 Novartis Corporation Process for the preparation of an optically pure enantiomer of formoterol
US5996576A (en) * 1995-09-27 1999-12-07 Glaxo Group Limited Atomising nozzle
US6030604A (en) * 1997-01-20 2000-02-29 Astra Aktiebolag Formulation for inhalation
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
US6227862B1 (en) * 1999-02-12 2001-05-08 Advanced Drivers Education Products And Training, Inc. Driver training system

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129245A1 (en) * 2000-05-19 2003-07-10 Eva Trofast Novel process
US7179489B2 (en) * 2000-05-19 2007-02-20 Astrazeneca Ab Process for preparing a pharmaceutical composition containing an active ingredient and a micronised carrier/diluent
US20070098644A1 (en) * 2005-10-31 2007-05-03 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
US20070207091A1 (en) * 2006-03-01 2007-09-06 Mcaffer Ian G C Nebulizer Formulation
US10716753B2 (en) 2009-05-29 2020-07-21 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
US20210308150A1 (en) * 2010-07-16 2021-10-07 Cipla Limited Pharmaceutical Compositions
US10226421B2 (en) 2013-04-10 2019-03-12 Zambon S.P.A. Pharmaceutical composition containing budesonide and formoterol

Also Published As

Publication number Publication date
SE9802073D0 (sv) 1998-06-11
DE69938390T2 (de) 2009-03-05
IL139921A (en) 2006-10-05
EP1316311A1 (en) 2003-06-04
IS5752A (is) 2000-12-05
WO1999064014A1 (en) 1999-12-16
ID27937A (id) 2001-05-03
JP2002517450A (ja) 2002-06-18
AU4671099A (en) 1999-12-30
EP1085877A1 (en) 2001-03-28
SA99200234B1 (ar) 2007-03-10
AU771715B2 (en) 2004-04-01
DK1085877T3 (da) 2008-06-09
DE69938390D1 (de) 2008-04-30
MY129281A (en) 2007-03-30
NO20006253L (no) 2001-02-12
EP2266574A1 (en) 2010-12-29
EE05661B1 (et) 2013-06-17
CZ20004593A3 (cs) 2001-04-11
CY1110376T1 (el) 2015-04-29
ATE389409T1 (de) 2008-04-15
CA2334411A1 (en) 1999-12-16
CN100389771C (zh) 2008-05-28
CA2334411C (en) 2008-07-15
HK1035145A1 (en) 2001-11-16
UA87956C2 (uk) 2009-09-10
AR018410A1 (es) 2001-11-14
HUP0103108A3 (en) 2002-11-28
PL344665A1 (en) 2001-11-19
ES2302384T3 (es) 2008-07-01
EE200000740A (et) 2002-04-15
HUP0103108A2 (hu) 2002-05-29
SK18882000A3 (sk) 2001-07-10
IL139921A0 (en) 2002-02-10
EP1085877B1 (en) 2008-03-19
ZA200006943B (en) 2002-02-27
BR9911073A (pt) 2001-02-20
NO20140823L (no) 2001-02-12
CN1305380A (zh) 2001-07-25
NZ536279A (en) 2007-01-26
SK286252B6 (sk) 2008-06-06
NO20006253D0 (no) 2000-12-08
KR20010052721A (ko) 2001-06-25
US9295644B2 (en) 2016-03-29
TR200003666T2 (tr) 2001-06-21
TWI252756B (en) 2006-04-11
CZ300874B6 (cs) 2009-09-02
PT1085877E (pt) 2008-05-13
NO20130269L (no) 2001-02-12
RU2222332C2 (ru) 2004-01-27
US20040063676A1 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
EP1085877B1 (en) Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
AU715319B2 (en) New combination
EP1014993A1 (en) New use for budesonide and formoterol
JP5492072B2 (ja) 喘息の増悪の予防および／または治療のためのフォルモテロールおよびジプロピオン酸ベクロメタゾンを含む組成物の使用
EP1009408A1 (en) New combination of antiasthma medicaments
HK1035145B (en) Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
HK1152252A (en) Therapeutic use on-demand of formoterol and budesonide
MXPA00011806A (en) Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
MXPA98004357A (en) New combination

Legal Events

Date Code Title Description
AS Assignment

Owner name: ASTRA AKTIEBOLAG, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EKSTROM, TOMMY;REEL/FRAME:010634/0814

Effective date: 19990615

AS Assignment

Owner name: ASTRAZENECA AB, SWEDEN

Free format text: CERTIFICATE OF REGISTRATION;ASSIGNOR:ASTRA AKTIEBOLAG;REEL/FRAME:011644/0299

Effective date: 20000215

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION